Welcome to our dedicated page for Regenerex Pharma news (Ticker: RGPX), a resource for investors and traders seeking the latest updates and insights on Regenerex Pharma stock.
Regenerex Pharma Inc (RGPX) drives innovation in therapeutic development through cutting-edge biotechnology research. This news hub provides investors and healthcare professionals with essential updates on clinical trial progress, regulatory milestones, and strategic corporate developments.
Access official press releases and verified news covering treatment advancements, financial performance, and industry partnerships. Our curated collection ensures timely updates on RGPX's work in improving patient outcomes through novel pharmaceutical solutions.
Discover updates spanning drug development pipelines, intellectual property achievements, and market expansion initiatives. Bookmark this page to stay informed about Regenerex Pharma's contributions to medical science and biotech investment opportunities.
Regenerex Pharma (OTC: RGPX), a developer of advanced wound closure systems, has signed a binding supply and development agreement with Holista Colltech Ltd. of Perth, Australia. The agreement grants Regenerex exclusive worldwide rights to use Holista's proprietary ovine collagen technologies in wound care applications.
The agreement includes minimum purchase commitments starting at $50,000 in 2025, scaling to $9 million annually from 2028. Regenerex will conduct FDA clinical studies and regulatory approvals, while both companies will collaborate on new nano-collagen applications in wound care. Manufacturing will be conducted at Holista's facilities in Collie and Malaysia under GMP standards.
Regenerex Pharma (OTC: RGPX) has announced a strategic licensing agreement with Holista Colltech Ltd. to incorporate ovine nano-collagen into its QBx™ wound healing technology. The integration aims to enhance deep tissue regeneration through improved scaffolding facilitation and cell proliferation.
The company will utilize Holista's high-purity ovine collagen, sourced from disease-free Australian sheep, which offers advantages over traditional bovine or porcine collagen sources. The nano-collagen's ultra-small molecular size creates an optimal scaffolding matrix for cellular growth, particularly beneficial for deep tissue regeneration cases.
